skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration


Amgen Inc. and Allergan PLC launched the first US biosimilars for Roche's Herceptin (trastuzumab) and Avastin (bevacizumab) on 18 July, also marking the first oncology biosimilar launches in the US.

Scrip reviewed Herceptin's rise and its coming fall in anticipation of near-term biosimilar product market entry, which wasn't expected until later this year or possibly in early 2020. Both Kanjinti (trastuzumab-anns) and Mvasi (bevacizumab-awwb) are priced at 15% discounts to Herceptin's and Avastin's list prices.

Scrip_Infographic_ Sunset_Begins_For_Roches_Herceptin_As_Amgen_Allergan_Biosimilar_Launches

Read also


Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: